Dept Of Hematology And Oncology | Germany
Dr. Sivahari Prasad Gorantla, born on July 25, 1980, in India, is a Junior Group Leader at the Signal Transduction Lab at the University Medical Center, Universitätsklinikum Schleswig-Holstein, Campus Lübeck. His research focuses on molecular therapeutics, targeted therapy, and drug resistance mechanisms. He is recognized for his groundbreaking work in the development of therapies targeting JAK2 and other kinases in myeloproliferative neoplasms.
Professional profile👤
Google Scholar
ORCID
Scopus
Strengths for the Awards✨
-
Extensive Research Experience: Dr. Gorantla’s research spans a wide range of significant areas, including molecular therapeutics, cancer research, and drug resistance mechanisms, making him a key contributor to advancements in these fields.
-
Outstanding Publication Record: His research publications in high-impact journals such as Nature Communications, Leukemia, and Molecular Oncology highlight his ability to generate novel and impactful insights in his field.
-
International Recognition and Honors: Dr. Gorantla has received multiple awards, including the “Young Investigator Prize” from DGHO and the “Abstract Achievement Award” from the American Association of Hematology. His recognition by prestigious organizations indicates his high standing in the scientific community.
-
Successful Grant Acquisition: His ability to secure substantial research grants from prestigious sources (e.g., DAAD, DFG, Wegener Foundation) is a testament to his research credibility and the relevance of his work.
-
Teaching and Mentoring: His involvement in teaching medical students and master’s students, particularly in the areas of molecular life sciences and genomics, showcases his dedication to education and mentoring the next generation of researchers.
Education 🎓
Dr. Gorantla completed his Ph.D. in Hematology and Oncology from Klinikum rechts der Isar, TUM in 2010. He then pursued multiple postdoctoral fellowships, including at the University Clinic Freiburg and the prestigious Hematology and Oncology department at TUM. His academic journey also includes a Master’s in Biotechnology from the University of Calicut.
Experience 💼
Dr. Gorantla’s career spans several key positions, including Assistant Professor at the University of Hyderabad, India, and Independent Postdoctoral Fellow at University Clinic Freiburg. His work involves leading research in molecular mechanisms behind cancer resistance to therapy and the development of novel therapeutic strategies. He currently holds his position as Junior Group Leader at the University Medical Center Lübeck.
Dr. Gorantla’s research revolves around molecular therapeutics, targeted therapy, and mechanisms of drug resistance, particularly in blood cancers like leukemia and myeloproliferative neoplasms. He has contributed to understanding the role of JAK2 and other kinases in resistance to treatment, paving the way for novel treatment strategies.
Awards 🏆
Throughout his career, Dr. Gorantla has earned several prestigious accolades. Notable among them are the Young Investigator Prize by DGHO (German Hematology Association) in 2010 and the Abstract Achievement Award from the American Association of Hematology in 2013. He has also been a finalist for the AACR Scholar-in-Training Award and won multiple travel awards at major hematology conferences.
Publications 📚
Dr. Gorantla has authored numerous impactful publications in the field of oncology. Some of his significant works include:
-
Gorantla SP, Rassner M, et al. Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is mediated mainly by targeting pro-inflammatory cytokine signaling not oncogenic signaling (Accepted in Nature Communications, 2024). Nature Communications
-
Gorantla SP, Oelschlager L, et al. Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation (Accepted in Leukemia, 2024). Leukemia Journal
-
Gorantla SP, Mueller TA, et al. A newly identified 45-kDa JAK2 variant (Mol Oncol, 2024). Mol Oncol
His work is widely cited in the field, with articles being referenced by researchers and clinicians worldwide.
Conclusion 🌍
Dr. Sivahari Prasad Gorantla has emerged as a leader in the field of molecular oncology, particularly in the development of targeted therapies for blood cancers. His dedication to research, extensive experience, and numerous accolades make him a valuable contributor to scientific advancements in cancer treatment. With ongoing research grants and fellowships, Dr. Gorantla continues to push the boundaries of medical science, offering new hope for cancer patients worldwide.
